MIT Engineers Develop Nanoparticle System for Personalized Cancer Vaccines

Researchers at MIT have engineered a nanoscale particle, a modified M13 bacteriophage, to serve as a customizable delivery vehicle for personalized cancer vaccines. This system, which can be coated with specific cancer antigens, successfully prevented colon tumor development in mice. This advance in materials science offers a customizable approach to vaccine development, potentially enabling tailored treatments for individual patients.